Development of a novel bispecific antibody GR1801 for rabies

文献类型： 外文期刊

第一作者： Long, Caifeng

作者： Long, Caifeng;Wang, Wenbo;Yu, Chuanfei;Wang, Lan;Hao, Xiaobo;Liu, Zhigang;Hao, Xiaobo;Bian, Lin;Liu, Zhigang;Feng, Ye;Tu, Changchun;Sun, Sheng;Feng, Ye;Tu, Changchun

作者机构：

关键词： bispecific antibody; glycoprotein; postexposure prophylaxis; rabies; rabies virus

期刊名称：JOURNAL OF MEDICAL VIROLOGY （ 影响因子：12.7； 五年影响因子：8.5 ）

ISSN： 0146-6615

年卷期： 2023 年 95 卷 8 期

页码：

收录情况： SCI

摘要： Rabies is a zoonotic viral disease characterized by an almost 100% fatality rate once symptoms appear. However, it can be prevented through timely postexposure prophylaxis (PEP). Currently, there is a growing trend to replace polyclonal rabies immune globulin (RIG) with monoclonal antibodies (mAbs) in rabies PEP. In this study, we developed a human bispecific antibody, GR1801, by combining two mAbs, A2 and B353, which target distinct epitopes. GR1801 is an asymmetric immunoglobulin G1 molecule, with one arm (A2 targeting epitope III) in fragment antigen-binding (Fab) form and the other arm (B353 targeting epitope I) in single-chain variable fragment (scFv) form, constructed using Knobs-into-Holes technology. GR1801 demonstrated the ability to neutralize 90 naturally occurring rabies virus (RABV) glycoprotein antigenic variants, 21 pseudotyped, and 18 live street RABVs, exhibiting broad-spectrum neutralizing activity. In vivo, GR1801 provided protection equivalent to that of human RIG in golden hamsters challenged with lethal RABV. In conclusion, these findings demonstrate the neutralization potency and breadth of GR1801, which can be a promising candidate drug for rabies PEP, and a comprehensive testing against a broad spectrum of Chinese prevalent RABVs will be investigated in great detail in the future for the in vitro and in vivo studies.

分类号：

  • 相关文献
作者其他论文 更多>>

微信小程序